Download free issues of Peer Perspectives in Oncology, our Insider Abstract series to help biotech CMOs get clinical results faster.
Adaptive Trial Design in Phase I and II, an interview with Cytel Inc. CEO Ranganath Nayak, Ph.D., discussing how adaptive trials are being successfully implemented in phase I and phase II clinical studies.
Context of Vulnerability: A Powerful New Paradigm in Targeted Drug Development: Medelis Advisory Board chair Dr. Dan Von Hoff discusses the use of "Context of Vulnerability" to improve efficacy with lower n in clinical trials.
Patient Safety in Clinical Trials: Dr. James Gourzis discusses factors that have launched patient safety to the forefront of public scrutiny, including the effects of increased reporting requirements.
Focusing unparalleled expertise on your research challenges
As a worldwide single-source provider for oncology drug development and clinical trial management, Medelis is helping biotechnology and pharmaceutical companies in the U.S., Europe and Asia by delivering the best total solution—and all the support required—to optimize the return on your clinical research investments. And we accomplish that in the quickest, most responsive way possible.
Specializing in oncology phase I, II and phase III trials
|
|
|
World-class expertise for your phase III drug candidates
Medelis' medical founders, team physicians and clinical trial management physicians are internationally-recognized oncology thought leaders. They organize and chair sessions at national and international oncology meetings and serve as officers and board members of professional oncology organizations, including The American Association for Cancer Research and The American Society of Clinical Oncology.
- Our team has managed phase I through phase III trials in the US, Canada and Europe.
- We offer extensive EDC experience
- We've worked with all different sponsor types: public and private, biotech and pharmaceutical, governmental, large and small, European and U.S.
- Our medical monitors are always board-certified oncologists.
- We’ve handled most targets within oncology.
- We also provide full preclinical research services.
In addition, our relationships within the oncology community allow us to bring aboard additional experienced resources if we run across that rare instance requiring a unique expertise.
Our approach is driven by a critical mass of clinical research expertise, the ability to identify and focus on the most significant challenges, and your need for prompt results. Our world-class insight and experience in the development and execution of clinical research plans and protocols delivers the decision support you need to chart your next clinical move.
» Contact us now to discuss your upcoming phase III clinical trial.
